Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.
15 results about "ASK1" patented technology
Filter
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Apoptosis signal-regulating kinase 1 (ASK1) also known as mitogen-activated protein kinase kinase kinase 5 (MAP3K5) is a member of MAP kinase kinase kinase family and as such a part of mitogen-activated protein kinase pathway. It activates c-Jun N-terminal kinase (JNK) and p38 mitogen-activated protein kinases in a Raf-independent fashion in response to an array of stresses such as oxidative stress, endoplasmic reticulum stress and calcium influx. ASK1 has been found to be involved in cancer, diabetes, rheumatoid arthritis, cardiovascular and neurodegenerative diseases.
The present invention relates to a triazole compound having a novel ring structure, a preparation method therefor, and a use thereof. The triazole compound having a novel ring structure according to the present invention exhibits excellent ASK1 inhibiting ability and inhibits apoptosis of neurons, and thus can be used for the prevention or treatment of ASK1-related diseases, including neurodegenerative diseases, cardiovascular diseases, autoimmune diseases, and liver diseases.
The present invention provides aromatic heterocyclic amide compounds and uses thereof. Specifically, such compounds can effectively inhibit ASK1 kinase activity. They are compounds represented by formulas (I) to (III), or tautomers, stereoisomers, hydrates, solvates, pharmaceutically acceptable salts, or prodrugs of the compounds represented by formulas (I) to (III): #imgabs0#
The present invention relates to: a triazole compound having a novel ring structure; a method for preparing same; and a use thereof. The triazole compound having a novel ring structure according to the present invention exhibits an excellent ability to inhibit ASK1 and inhibits the apoptosis of neurons, and thus can be used for preventing or treating ASK1-related diseases including neurodegenerative diseases, cardiovascular diseases, autoimmune diseases, and liver diseases.
The present disclosure relates to a triazole compound having a novel ring structure; a method for preparing same; and a use thereof. The triazole compound having a novel ring structure according to the present disclosure exhibits an excellent ability to inhibit ASK1 and inhibits the apoptosis of neurons and thus can be used for preventing or treating ASK1-related diseases including neurodegenerative diseases, cardiovascular diseases, autoimmune diseases, and liver diseases.
The present invention relates to a class of small molecule inhibitors of ASK1 kinase, and specifically to the synthesis and application of a small molecule compound having a 2-pyridine-substituted carboxamide structure, as well as a pharmaceutical composition thereof and its use in preparing ASK1 small molecule inhibitors, or in drugs for preventing and / or treating ASK1-related diseases, especially liver diseases, lung diseases, tumors, cardiovascular diseases, kidney diseases and metabolic diseases.
The invention discloses preparation and application of a compound with a 1H-benzimidazole structure, the compound is a novel amide compound, the preparation process is simple and easy to implement, and the compound can be prepared by only one step; the compound with the 1H-benzimidazole structure, which is synthesized by utilizing the existing compound, can be used as an ASK1 inhibitor and is applied to medicines for preventing or treating apoptosissignal-regulating kinase 1 (ASK1)-mediated diseases or symptoms.
A small molecule polypeptide AIP203, the amino acid sequence of which is shown in SEQ ID NO.1, can be seen from cell experiments: the plasmid expressing AIP203 is transferred into HEK293T cells, and IP experiments show that AIP203 reduces the N-terminal dimerization of ASK1, and the chronic disease overexpressing AIP203 is transfected into RAW264.7 cells, mouse primary hepatocytes (PMH) or human umbilical vein endothelial cells (HUVEC) to reduce JNK phosphorylation in inflammatory response and inhibit the level of MMP9 or inflammatory factors. These results show that AIP203 targets the N-terminal dimerization of ASK1 and antagonizes macrophage inflammation, and can be used as a new anti-inflammatory polypeptide.